How many clinical trials are tracked for Skin Neoplasms?

5 trials are tracked, 1 with published results.

Skin Neoplasms Research

Skin Neoplasms: what the trials found

Clinical evidence regarding the management of skin neoplasms includes data on 5-fluorouracil and sirolimus. For patients treated with 5-fluorouracil, there was no statistically significant difference in the time to diagnosis of the first keratinocyte carcinoma (KC) on the face or ears requiring surgery (p=0.93), nor was there a significant difference in the hazard ratio for surgically treated KC (p=0.93).

Sirolimus demonstrated significant efficacy in reducing new biopsy-confirmed nonmelanoma skin cancer (NMSC) lesions per subject per year (1.31 vs 2.48, p=0.022). Furthermore, sirolimus was associated with a significantly shorter time to the first biopsy-confirmed new NMSC lesion (380 vs 163 days, p=0.047) and a higher number of lesion-free subjects (17 vs 9, p=0.015).

For the clinician treating this condition

Sirolimus significantly reduces the annual rate of new biopsy-confirmed NMSC lesions and increases the number of lesion-free subjects.
5-fluorouracil did not demonstrate a statistically significant impact on the timing or hazard ratio for surgically treated keratinocyte carcinomas on the face or ears.

AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.